Hospira is voluntarily recalling three lots of the injectable opioid medication Hydromorphone HCl because the glass vials may be broken or cracked, the Food and Drug Administration announced yesterday. Hospira has notified hospitals and others with an existing inventory of the lots subject to this recall that they should stop use and distribution of the remaining units and quarantine them immediately. See the FDA announcement for more information, including the lot numbers. Health care professionals are encouraged to report any related problems or events to the FDA's MedWatch Program. Last week, the AHA and others asked the Drug Enforcement Administration to temporarily adjust the aggregate production quotas for certain injectable opioid medications in short supply to allow other manufacturers to supply product until the shortages resolve.
 

Related News Articles

Headline
Civica Rx, the not-for-profit generic drug company, officially opened its headquarters last week in Lehi, Utah.
Blog
We must address the racial, ethnic and socioeconomic disparities that increase the risk of negative perinatal outcomes for women of color.
Blog
AHA Executive Vice President Maryjane Wurth previews AHA’s Team Training Conference, where different interdisciplinary groups from diverse health care settings…
Headline
The Food and Drug Administration today ordered manufacturers to immediately stop selling and distributing surgical mesh products for transvaginal repair of…
Headline
Readmissions penalties for hospitals with the greatest share of dually eligible beneficiaries could fall by an estimated $22.4 million in fiscal year 2019,…
Headline
The Centers for Medicare…